Interestingly, a model of Dnmt3a-driven CHIP demonstrated that acquiring Npm1 mutations can lead to the development of myeloproliferative disorders (MPD), and additional transplantation leads to AML (SanMiguel et al., 2022). Here, DNMT3A is linked to myeloproliferative disorder.